Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Waste Data Preview
In 2023, Regeneron Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
Insights into Regeneron Pharmaceuticals's Waste Treatment Practices
In 2023, Regeneron Pharmaceuticals generated a total of 7,360 metric tonnes of waste.
Of this amount, 90.81% of Regeneron Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 9.19% was disposed of through landfilling, incineration, or combustion.
Regeneron Pharmaceuticals's Waste Recovery Rate
How much of Regeneron Pharmaceuticals's waste is recycled or recovered?
In 2023, Regeneron Pharmaceuticals reported a total waste generation of 7,360 metric tonnes, of which 90.81% was recovered through recycling, reuse, or composting. This high recovery rate suggests that Regeneron Pharmaceuticals has implemented strong circular economy practices and actively prioritizes sustainable waste management.
Has Regeneron Pharmaceuticals reduced its environmental waste footprint over time?
Since 2020, Regeneron Pharmaceuticals's total waste generation increased by 18.52%, but declined by 10.24% in the year 2023, suggesting a potential shift toward more efficient material use or the early impact of waste reduction strategies.
Over the same period, Regeneron Pharmaceuticals's waste recovery rate declined by 4.36%, and then remained stable in 2023, possibly indicating that earlier setbacks have leveled off without signs of active improvement.
Overall, Regeneron Pharmaceuticals’s waste generation and recovery data show a mixed and inconsistent trend. A deeper analysis of the company's activities, industry benchmarks, and operational changes is needed to assess its sustainability performance more precisely.
Regeneron Pharmaceuticals’s Waste Recovery vs. Disposal Over Time
- Total Waste Disposed
- Total Waste Recovered
Insights into Regeneron Pharmaceuticals’s Generation of Hazardous and Non-Hazardous Waste
In 2023, Regeneron Pharmaceuticals generated a total of 7,360 metric tonnes of waste.
Of this amount, 18.75% of Regeneron Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 81.25% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Regeneron Pharmaceuticals’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How Regeneron Pharmaceuticals reduced the environmental impact of its waste?
Since 2020, Regeneron Pharmaceuticals's total waste generation increased by 18.52%, including a 10.24% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, the share of hazardous waste in Regeneron Pharmaceuticals's total output increased by 10.89%, including a further 9.04% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.
Overall, while Regeneron Pharmaceuticals has recently reduced waste output, its hazardous waste share continues to rise, raising concerns about treatment efficiency or growing reliance on harmful materials despite short-term volume improvements.
How does Regeneron Pharmaceuticals treat its hazardous waste?
In 2023, Regeneron Pharmaceuticals reported that 1,380 metric tonnes of its total waste output were classified as hazardous. This represents 18.75% of its overall waste generation.
The company treated this hazardous waste using a combination of methods. A majority (64%) was diverted from disposal through recovery-oriented treatments such as recycling or reuse. This suggests that Regeneron Pharmaceuticals has established processes to reduce the environmental burden of its most harmful waste streams.